Právní předpis byl sestaven k datu 19.09.2014.
Zobrazené znění právního předpisu je účinné od 20.12.2013 do 19.09.2014.
98
XXXXXXX
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,
xxxxxx xx mění x xxxxxxxx xxxxxxx Xxxxxxxxxxxx zahraničních věcí x. 58/2007 Xx. x. s. a x. 46/2008 Sb. x. x. x xxxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 97/2012 Xx. x. x. o Mezinárodní xxxxxx proti xxxxxxx xx xxxxxx
Xxxxxxxxxxxx zahraničních xxxx xxxxxxx, že dne 12. xxxxxxxxx 2012 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX oznámeno xxxxxxxxx xxxxxx znění Xxxxxxx X - Seznamu xxxxxxxxxx látek a xxxxx - Xxxxxxxxxxx xxxxxxxx Mezinárodní úmluvy xxxxx xxxxxxx xx xxxxxx1).
X xxxxx xxxxxx Xxxxxxx I xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx.
Nové xxxxx Přílohy I xxxxxxxxx v platnost x xxxxxxx s xxxxxxx 34 xxxx. 3 Úmluvy xxx 1. ledna 2013 x xxxxx xxxx xxxxxxxxx x platnost x xxx Xxxxxx xxxxxxxxx. Xxxx xxxxxx xxxxxx znění Xxxxxxx X x platnost xxxxxxxx platit xxxxx Xxxxxxx X Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx sportu xxxxxx xx 1. xxxxx 2012 x vyhlášené xxx č. 97/2012 Sb. m. s.
Xxxxxxxx xxxxx Xxxxxxx I x xxxx překlad xx xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.
1) Xxxxxxxxxxx xxxxxx proti dopingu xx xxxxxx přijatá xxx 19. xxxxx 2005 x Xxxxxx xxxx vyhlášena pod č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
XXXXXXX I
XXXXXX XXXXXXXXXX XXXXX X METOD XXXXXXX XXX ROK 2013
XXXXXXX XXXXXXXXXXXXX XXXXX
Xxxxxx od 1. xxxxx 2013
Podle xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx všechny Xxxxxxxx xxxxx xxxxx xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" kromě xxxxx xx xxxxxx X1, X2, X4.4, X4.5 x X6(x) x Xxxxxxxxxx xxxxx X1, X2 a X3.
| &xxxx;
XXXXX X XXXXXX ZAKÁZANÉ XXXXX
(XXX XXXXXXX X MIMO XXXXXX)
|
XXXXXXXX XXXXX
X0. XXXXXXXXXXX XXXXX
Jakákoliv xxxxxxxxxxxxx látka, která xxxx zahrnuta x xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx aktuálně xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (např. xxxxxx x xxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxx xxxx xx xxxxxxxx xxxxxxxxxx, syntetické drogy, xxxxxxxxxxx xxxx), xx xxxxxxxx stále.
S1. XXXXXXXXXX XXXXX
Xxxxxxxxxx xxxxx xxxx xxxxxxxx.
1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (AAS):
(x) Xxxxxxxx* XXX, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; boldenon; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazol); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; ethylestrenol (19-xxx-17α-xxxxx-4-xx-17-xx); fluoxymesteron; xxxxxxxxxx; xxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); gestrinon; 4-xxxxxxxxxxxxxxxxxx (4,17β-dihydroxyandrost-4-en-3-on); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-hydroxy-17α-methyl-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; metribolon (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx; xxxxxxxxx; 19-norandrostendion (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; norethandrolon; xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxxxxx [3,2-x]xxxxxxx); xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-homo-pregna-4,9,11-trien-17β-ol-3-on); trenbolon x další xxxxx x xxxxxxxx chemickou xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxx** XXX, pokud xxxx podány xxxxxxxx:
Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, prasteron (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-xxxxxxxxxxxxxx-5-xx-17-xxx), xxxxxxxxxxx x jejich xxxxxxxxxx x isomery, xxx xx x xxxxxxxx xxxxx xx xx:
| &xxxx;
5α-xxxxxxxxx-3α,17α-xxxx
|
&xxxx;
5-xxxxxxxxxxxxx (androst-5-en-3,17-dion)
|
|
5α-androstan-3α,17β-diol
|
|
|
5α-androstan-3β,17α-diol
|
epi-dihydrotestosteron
|
|
5α-androstan-3β,17β-diol
|
epitestosteron
|
|
androst-4-en-3α,17α-diol
|
3α-hydroxy-5αandrostan-17-on
|
|
androst-4-en-3α,17β-diol
|
3β-hydroxy-5αandrostan-17-on
|
|
androst-5-en-3β,17α-diol
|
7α-hydroxy-DHEA
|
|
androst-5-en-3α,17α-diol
|
7β-hydroxy-DHEA
|
|
androst-5-en-3α,17β-dioI
|
7-keto-DHEA
|
|
androst-5-en-3β,17α-diol
|
19-norandrosteron
|
|
4-androstendiol (xxxxxxx-4-xx-3β,17β-xxxx)
|
&xxxx;
19-xxxxxxxxxxxxxxxxx
|
2. Xxxxxxx anabolické xxxxx, xxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, zilpaterol, xxx xx x omezením xxxxx xx xx.
| &xxxx;
Xxx xxxxx skupiny xxxx xxxxx: * "exogenní" xx xxxxxxxx x xxxxx, xxxxxx tělo xxxx xxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx k xxxxx, xxxxxx xxxx tělo xxxxxxxxxx xxxxxxxxx.
|
X2. PEPTIDOVÉ XXXXXXX, XXXXXXX XXXXXXX A XXXXXXXX XXXXX
Následující xxxxx x xxxxxx xxxxxxxxxx faktory xxxx xxxxxxxx:
1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxx. xxxxxxxxxxxx (XXX), xxxxxxxxxxx (xXXX), xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (HIF), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX), xxxxxxxxxxx /Hematide/);
2. Xxxxxxxxxxxxxxxxxx (CG) x Xxxxxxxxxxxx hormon (LH) x xxxx;
3. Xxxxxxxxxxxxxx;
4. Xxxxxxx xxxxxx (XX), fibroblastové xxxxxxx xxxxxxx (FGFs), xxxxxxxxxxxx xxxxxxx xxxxxx (XXX), insulinu podobný xxxxxxx xxxxxx-1 (XXX-1), xxxxxxxxxx růstové faktory (XXX), xxxxxxx faktor xxxxxxxx x krevních xxxxxxxx (XXXX) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX), xxxxxx xxxx xxxxxxxxx xxxx xxxxxxx xxxxxxx ovlivňující xxxxxxx xxxx degradaci xxxxxxxx xxxxx, šlach x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx energie, xxxxxxxxxxxxx xxxxxxxx nebo xxxxxxxxxxx xxxx svalových vláken;
x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.
X3. XXXX2- XXXXXXXX
Xxxxxxx xxxx-2 agonisté xxxxxx xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. x- x x-), jsou xxxxxxxx xxxxx salbutamolu (xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx), xxxxxxxxxxx (xxxxxxxxx 36 xxxxxxxxxx xx 24 xxxxx) x salmeterolu xxxxx xxxx xxxxxx x xxxxxxxx x xxxxxxx s doporučeným xxxxxxxx xxxxxxx xxxxxxx.
Xxxxxxxxxx xxxxxxxxxxx x xxxx x koncentraci xxxxx xxx 1000 xx/xx x xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 40 ng/ml xxxxxx považována za xxxxxxxxx xxxxxxxxxxxx použití, xxx bude xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx farmakokinetickou xxxxxx, že xxxxxxxxxx xxxxxxxx byl xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx xxxxx xxx xxxx xxxxxxx xxxxxxx.
X4. XXXXXXXXX A XXXXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, androsta-1,4,6-trien-3-17-dion (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-xxx),xxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.
2. Xxxxxxxxxx xxxxxxxxxx estrogenových receptorů (XXXX), zahrnující:
Xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.
3. Xxxxxxx antiestrogenní xxxxx zahrnující:
Xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, ale xx x omezením xxxxx xx xx.
4. Xxxxx xxxxxxxxxxxx xxxxxx myostatinu xxxxxx xxxxxxxxxx xxxxxxxxxx, ale xx x omezením xxxxx xx ně.
5. Xxxxxxxxxxx xxxxxxxxxx:
x) Xxxxxxxx;
x) Xxxxxxxx xxxxx aktivovaný xxxxxxxxxxxxxx xxxxxxxxxxxxx /Peroxisome Xxxxxxxxxxxx Activated Receptor δ (XXXXδ) xxxxxxxx/ (xxxx. XX 1516) x Xxxxxxxx xxxxxxxxxxxxxxx xxx aktivované XXX x součinnosti s XXXX delta /PPARδ-AMP-activated xxxxxxx kinase (XXXX) xxxx agonists/ (xxxx. XXXXX)
X5. XXXXXXXXX X XXXXXXX XXXXXXXXX XXXXX
Maskovací látky xxxx xxxxxxxx. Zahrnují:
Xxxxxxxxx, xxxxxxxxxxxx, plasmaexpandery (xxxx. xxxxxxxx, nitrožilní xxxxxx albuminu, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx. Lokální xxxxxx felypressinu xxx xxxxx xxxxxxxx není xxxxxxxx.
Xxxxxxxxx xxxxxxxx:
Xxxxxxxxxxxx, amilorid, bumetanid, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxx etakrynová, xxxxxxxxx, spironolakton, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, hydrochlorothiazid, xxxxxxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx (xxxxx drospirenonu, xxxxxxxxx x lokálního xxxxxx dorzolamidu x xxxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx).
Pro xxxxxxx (Xxx Xxxxxxx, xxxxxxxx Xxxx Xxxxxx) jakéhokoliv xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx x pseudoefedrin) xx xxxxxxx x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx xx xxxxxxxxxx xxxxxxx xxxxxxxxxx Xxxxxxxxxxxx xxxxxxx na xxxx látku xxxxx x xx, xxxxx xxx byla xxxxxxx xx diuretikum xxxx xxxxx maskovací látku.
ZAKÁZANÉ XXXXXX
X1. XXXXXXXXXX X KRVÍ X XXXXXXXX KOMPONENTAMI
Zakázané xx xxxxxxxxxxx:
1. Xxxxxx xxxx znovuzavedení xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx krve nebo xxxxxxxxx xxxxxxx a xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx.
2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx, zahrnující xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (např.krevní xxxxxxxx založené xx xxxxxxxxxxx, mikroenkapsulované xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (XXX13), xxx ne x xxxxxxxx xxxxx xx ně. Xxxxxxxxxxxx xxxxxxxx xxxxxxxx není.
3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx x xxxxxxxx komponentami fyzikálními xxxx xxxxxxxxxx způsoby.
X2. XXXXXXXX A XXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxx, nebo xxxxx x xxxxxx, xx xxxxxx porušit integritu x xxxxxxxx Vzorků xxxxxxxxxx při Xxxxxxxxx xxxxxxxx je zakázané. Xx zahrnuje xxxxxx x/xxxx xxxxxx (xxxx. xxxxxxxxxx) xxxx, xxx xx x xxxxxxxx xxxxx xx xx.
2. Nitrožilní xxxxxx x/xxxx injekce xxxx xxx 50 ml xx 6 xxxxx xxxx zakázány xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x průběhu xxxxxxxxxxxx xxxxxxx nebo klinických xxxxxxxxxxxxx metod.
X3. XXXXXX DOPING
Z xxxxxx xxxxxxxxxx xx xxxxxxx sportovního xxxxxx xx xxxxxxxx následující:
1. Xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxxx;
2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx buněk;
|
LÁTKY X XXXXXX ZAKÁZANÉ XXX XXXXXXX
|
Xxxxx xxxxxxxxx S0 xx X5 x X1 xx M3 xxxxxxxxx xxxx jsou Xxx Xxxxxxx xxxxxxxx x xxxxxxxxxxx skupiny:
XXXXXXXX LÁTKY
X6. XXXXXXXXXXX
Xxxxxxx xxxxxxxxxxx xxxxxx všech xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. d- a x-) xxxx zakázaná, x xxxxxxxx xxxxxxxx xxxxxxxxx v případě xxxxxx místního xxxxxxx x xxxxxxxxxxx xxxxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2013*.
Xxxxxxxxxxx zahrnují:
(x) Xxxxxxxxxxxx xxxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxxx, amfetaminil, amfetamin, xxxxxxxxxx, benfluorex, xxxxxxxxxxx, xxxxxxxxxxxxxxx, bromantan, dimethylamfetamin, xxxxxxxxxxxxxx, xxxxxxxxxxx, fendimetrazin, xxxxxxxxx, xxxxxxxxxxx, fenkamin, xxxxxxxxxxx, xxxxxxxxxxx, fentermin, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, xxxxxxxxxxx, kokain, xxxxxxxxxxx, xxxxxxxxxx, mefenorex, xxxxxxxxxxx, xxxxxxxxxxxx (x-), xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, p-methylamfetamin, xxxxxxxxxx, xxxxxxxxx.
Xxxxxxxxxxxx, které xxxx xxxxxxxx xxxxxxx x xxxxx odstavci, xx Xxxxxxxxxxx xxxxxx.
(x) Specifická xxxxxxxxxxx (xxxxxxxx):
Adrenalin**, xxxxx***, xxxxxxx****, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, levmetamfetamin, xxxxxxxxxxxx, xxxxxxxxxxxx****, methylfenidát, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, pemolin, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
* Xxxxxxxxxxx xxxxx xxxxxxxx do Xxxxxxxxxxxxxx xxxxxxxx 2013 (xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxx) xxxxxx xxxxxxxxxx xx Xxxxxxxx látky.
** Lokální podání xxxxxxxxxx (např. xxxxx, xxxx xxxxxxxx) xxxx xxxx xxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.
*** Xxxxx xx xxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx moči.
**** Xxxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxx při xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx x 1 ml moči.
***** Xxxxxxxxxxxxx xx xxxxxxx, xxxxx xxxx xxxxxxxxxxx x moči xx xxxxx xxx 150 mikrogramů xx xxxxxxxx
X7. XXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
Xxxxxxxxxxx, dextromoramid, xxxxxxxxx(xxxxxx), xxxxxxxx a xxxx xxxxxxxx, xxxxxxxxxxx, metadon, xxxxxx, xxxxxxxx, oxymorfon, xxxxxxxxxx, xxxxxxx.
S8. XXXXXXXXXXX
Xxxxxxxx (xxxx. xxxxx, xxxxxx x xxxxxxxxx) nebo xxxxxxxxxx xxxxx9-xxxxxxxxxxxxxxxxxxx (THC) x xxxxxxxxxxxxxx (xxxx. "Xxxxx" /XXX018, JWH073/ x XX-210) xxxx zakázané.
X9. XXXXXXXXXXXXXXXXXXXX
Xxxxxxx xxxxxxxxxxxxxxxxxxxx podávané orálně, xxxxxxxx, xxxxxxxxxx nebo xxxxxxxxxxxxx xxxxxxxx jsou xxxxxxxx.
| &xxxx;
LÁTKY XXXXXXXX X URČITÝCH XXXXXXXX
|
P1. XXXXXXX
Xxxxxxx (xxxxxx) xx xxxxxxxx pouze Xxx Xxxxxxx x následujících xxxxxxxx. Xxxxxxx xx xxxx xxxxxxxx dechovou xxxxxxxx a/nebo xxxxxxxx xxxx. Xxxxxxx xxxxxxx xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) xx 0.10 g/l.
∙ Automobilový xxxxx (XXX)
∙ Xxxxxx (XXX)
∙ Xxxxxxx xxxxxx a xxxxxxxxxxxx(XXX)
∙ Xxxxxxxxxxx (XXXX)
∙ Xxxxxxxxxxx xxxxx (XXX)
∙ Vodní xxxxxxxxxx (UIM)
P2. XXXX-XXXXXXXXX
Pokud xxxx xxxxx xxxxxx, xxxx-xxxxxxxxx xxxx zakázány xxxxx Xxx Soutěži x xxxxxxxxxxxxx xxxxxxxx.
∙ Xxxxxxxxxxxx sport (XXX)
∙ Xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)
∙ Xxxx (IGF)
∙ Xxxxxxxxxxx (XXXX, XXX) (xxxxxxxx také Xxxx xxxxxx)
∙ Lyžování (XXX) - skoky xx xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx x X-xxxxx,x xxxxxxxxx X-xxxxx x "xxx xxx"
∙ Xxxxxxx (ISSF, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)
∙ Xxxxx (WDF)
Beta-blokátory xxxxxxxx xxxxxxxxxxx xxxxx:
Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, esmolol, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, nadolol, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.
Xxxxxxxxx
Xxxxxx předpis x. 98/2013 Xx. x. x. xxxxx účinnosti xxxx 20.12.2013.
Xxxxxx xxxxxxx x. 98/2013 Xx. m. x. xxx xxxxxx právním xxxxxxxxx č. 47/2014 Sb. m. s. s xxxxxxxxx xx 20.9.2014.
Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx v xxxxxxxx xxxx aktualizováno, xxxxx xx jich xxxxxx xxxxxxxxx xxxxx xxxxx uvedeného xxxxxxxx xxxxxxxx.